nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—CYP3A7—Progesterone—uterine cancer	0.111	0.17	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Progesterone—uterine cancer	0.111	0.17	CbGbCtD
Nefazodone—CYP3A5—Progesterone—uterine cancer	0.0835	0.128	CbGbCtD
Nefazodone—ABCB1—Progesterone—uterine cancer	0.0543	0.083	CbGbCtD
Nefazodone—CYP2D6—Progesterone—uterine cancer	0.0512	0.0782	CbGbCtD
Nefazodone—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0491	0.0751	CbGbCtD
Nefazodone—ABCB1—Dactinomycin—uterine cancer	0.0431	0.0658	CbGbCtD
Nefazodone—CYP3A5—Etoposide—uterine cancer	0.0374	0.0571	CbGbCtD
Nefazodone—CYP3A4—Progesterone—uterine cancer	0.0326	0.0497	CbGbCtD
Nefazodone—ABCB1—Etoposide—uterine cancer	0.0243	0.0371	CbGbCtD
Nefazodone—ABCB1—Doxorubicin—uterine cancer	0.0166	0.0253	CbGbCtD
Nefazodone—CYP2D6—Doxorubicin—uterine cancer	0.0156	0.0239	CbGbCtD
Nefazodone—CYP3A4—Etoposide—uterine cancer	0.0146	0.0223	CbGbCtD
Nefazodone—CYP3A4—Doxorubicin—uterine cancer	0.00994	0.0152	CbGbCtD
Nefazodone—HTR2A—artery—uterine cancer	0.000488	0.059	CbGeAlD
Nefazodone—ADRA1B—renal system—uterine cancer	0.000472	0.0572	CbGeAlD
Nefazodone—SLC6A2—decidua—uterine cancer	0.000291	0.0352	CbGeAlD
Nefazodone—HTR1A—renal system—uterine cancer	0.000288	0.0348	CbGeAlD
Nefazodone—ADRA1A—epithelium—uterine cancer	0.000286	0.0346	CbGeAlD
Nefazodone—Mood swings—Epirubicin—uterine cancer	0.00028	0.00083	CcSEcCtD
Nefazodone—Loss of consciousness—Etoposide—uterine cancer	0.000279	0.000828	CcSEcCtD
Nefazodone—Cerebrovascular accident—Doxorubicin—uterine cancer	0.000279	0.000828	CcSEcCtD
Nefazodone—Ataxia—Epirubicin—uterine cancer	0.000278	0.000824	CcSEcCtD
Nefazodone—ADRA2A—myometrium—uterine cancer	0.000277	0.0335	CbGeAlD
Nefazodone—Cough—Etoposide—uterine cancer	0.000277	0.000822	CcSEcCtD
Nefazodone—Convulsion—Etoposide—uterine cancer	0.000275	0.000816	CcSEcCtD
Nefazodone—Dehydration—Epirubicin—uterine cancer	0.000275	0.000815	CcSEcCtD
Nefazodone—Hyponatraemia—Doxorubicin—uterine cancer	0.000274	0.000814	CcSEcCtD
Nefazodone—Hypertension—Etoposide—uterine cancer	0.000274	0.000813	CcSEcCtD
Nefazodone—HTR2C—female reproductive system—uterine cancer	0.000274	0.0331	CbGeAlD
Nefazodone—Gastrointestinal haemorrhage—Doxorubicin—uterine cancer	0.000273	0.000811	CcSEcCtD
Nefazodone—Osteoarthritis—Doxorubicin—uterine cancer	0.000273	0.000811	CcSEcCtD
Nefazodone—Diplopia—Doxorubicin—uterine cancer	0.000273	0.000811	CcSEcCtD
Nefazodone—Liver function test abnormal—Epirubicin—uterine cancer	0.000273	0.000809	CcSEcCtD
Nefazodone—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000272	0.000809	CcSEcCtD
Nefazodone—Dry skin—Epirubicin—uterine cancer	0.000271	0.000803	CcSEcCtD
Nefazodone—Chest pain—Etoposide—uterine cancer	0.00027	0.000802	CcSEcCtD
Nefazodone—Orthostatic hypotension—Epirubicin—uterine cancer	0.00027	0.000801	CcSEcCtD
Nefazodone—Affect lability—Doxorubicin—uterine cancer	0.000269	0.000798	CcSEcCtD
Nefazodone—Migraine—Doxorubicin—uterine cancer	0.000269	0.000798	CcSEcCtD
Nefazodone—Discomfort—Etoposide—uterine cancer	0.000267	0.000792	CcSEcCtD
Nefazodone—Aspartate aminotransferase increased—Epirubicin—uterine cancer	0.000266	0.000789	CcSEcCtD
Nefazodone—ADRA1A—renal system—uterine cancer	0.000265	0.0321	CbGeAlD
Nefazodone—Face oedema—Doxorubicin—uterine cancer	0.000264	0.000783	CcSEcCtD
Nefazodone—Hypersensitivity—Dactinomycin—uterine cancer	0.000264	0.000782	CcSEcCtD
Nefazodone—Gastritis—Epirubicin—uterine cancer	0.000261	0.000776	CcSEcCtD
Nefazodone—Confusional state—Etoposide—uterine cancer	0.000261	0.000775	CcSEcCtD
Nefazodone—Alanine aminotransferase increased—Epirubicin—uterine cancer	0.00026	0.000773	CcSEcCtD
Nefazodone—SLC6A4—female reproductive system—uterine cancer	0.00026	0.0314	CbGeAlD
Nefazodone—Anaphylactic shock—Etoposide—uterine cancer	0.000259	0.000769	CcSEcCtD
Nefazodone—Mood swings—Doxorubicin—uterine cancer	0.000259	0.000768	CcSEcCtD
Nefazodone—Infection—Etoposide—uterine cancer	0.000257	0.000763	CcSEcCtD
Nefazodone—Abdominal distension—Epirubicin—uterine cancer	0.000257	0.000763	CcSEcCtD
Nefazodone—Ataxia—Doxorubicin—uterine cancer	0.000257	0.000763	CcSEcCtD
Nefazodone—Asthenia—Dactinomycin—uterine cancer	0.000257	0.000762	CcSEcCtD
Nefazodone—Asthma—Epirubicin—uterine cancer	0.000255	0.000758	CcSEcCtD
Nefazodone—Influenza—Epirubicin—uterine cancer	0.000255	0.000758	CcSEcCtD
Nefazodone—Dysphagia—Epirubicin—uterine cancer	0.000255	0.000758	CcSEcCtD
Nefazodone—Dehydration—Doxorubicin—uterine cancer	0.000254	0.000754	CcSEcCtD
Nefazodone—Thrombocytopenia—Etoposide—uterine cancer	0.000254	0.000752	CcSEcCtD
Nefazodone—Tachycardia—Etoposide—uterine cancer	0.000253	0.00075	CcSEcCtD
Nefazodone—Liver function test abnormal—Doxorubicin—uterine cancer	0.000252	0.000749	CcSEcCtD
Nefazodone—Dry skin—Doxorubicin—uterine cancer	0.00025	0.000743	CcSEcCtD
Nefazodone—Hyperhidrosis—Etoposide—uterine cancer	0.00025	0.000743	CcSEcCtD
Nefazodone—Orthostatic hypotension—Doxorubicin—uterine cancer	0.00025	0.000741	CcSEcCtD
Nefazodone—Angina pectoris—Epirubicin—uterine cancer	0.000249	0.000738	CcSEcCtD
Nefazodone—Anorexia—Etoposide—uterine cancer	0.000247	0.000733	CcSEcCtD
Nefazodone—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.000246	0.00073	CcSEcCtD
Nefazodone—Bronchitis—Epirubicin—uterine cancer	0.000245	0.000729	CcSEcCtD
Nefazodone—Diarrhoea—Dactinomycin—uterine cancer	0.000245	0.000727	CcSEcCtD
Nefazodone—Hypotension—Etoposide—uterine cancer	0.000242	0.000718	CcSEcCtD
Nefazodone—Gastritis—Doxorubicin—uterine cancer	0.000242	0.000718	CcSEcCtD
Nefazodone—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000241	0.000715	CcSEcCtD
Nefazodone—Dysuria—Epirubicin—uterine cancer	0.000239	0.000708	CcSEcCtD
Nefazodone—Abdominal distension—Doxorubicin—uterine cancer	0.000238	0.000706	CcSEcCtD
Nefazodone—Influenza—Doxorubicin—uterine cancer	0.000236	0.000701	CcSEcCtD
Nefazodone—Dysphagia—Doxorubicin—uterine cancer	0.000236	0.000701	CcSEcCtD
Nefazodone—Asthma—Doxorubicin—uterine cancer	0.000236	0.000701	CcSEcCtD
Nefazodone—Pollakiuria—Epirubicin—uterine cancer	0.000236	0.0007	CcSEcCtD
Nefazodone—Photosensitivity reaction—Epirubicin—uterine cancer	0.000233	0.000691	CcSEcCtD
Nefazodone—Paraesthesia—Etoposide—uterine cancer	0.000233	0.00069	CcSEcCtD
Nefazodone—Weight increased—Epirubicin—uterine cancer	0.000232	0.000689	CcSEcCtD
Nefazodone—Weight decreased—Epirubicin—uterine cancer	0.000231	0.000685	CcSEcCtD
Nefazodone—Dyspnoea—Etoposide—uterine cancer	0.000231	0.000685	CcSEcCtD
Nefazodone—Somnolence—Etoposide—uterine cancer	0.00023	0.000683	CcSEcCtD
Nefazodone—Angina pectoris—Doxorubicin—uterine cancer	0.00023	0.000683	CcSEcCtD
Nefazodone—Pneumonia—Epirubicin—uterine cancer	0.000229	0.000679	CcSEcCtD
Nefazodone—SLC6A2—female reproductive system—uterine cancer	0.000229	0.0277	CbGeAlD
Nefazodone—Vomiting—Dactinomycin—uterine cancer	0.000227	0.000675	CcSEcCtD
Nefazodone—Bronchitis—Doxorubicin—uterine cancer	0.000227	0.000674	CcSEcCtD
Nefazodone—CYP3A5—uterine cervix—uterine cancer	0.000226	0.0274	CbGeAlD
Nefazodone—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.000226	0.00067	CcSEcCtD
Nefazodone—Rash—Dactinomycin—uterine cancer	0.000226	0.00067	CcSEcCtD
Nefazodone—Decreased appetite—Etoposide—uterine cancer	0.000225	0.000668	CcSEcCtD
Nefazodone—Stomatitis—Epirubicin—uterine cancer	0.000222	0.000658	CcSEcCtD
Nefazodone—Constipation—Etoposide—uterine cancer	0.000221	0.000657	CcSEcCtD
Nefazodone—Pain—Etoposide—uterine cancer	0.000221	0.000657	CcSEcCtD
Nefazodone—Conjunctivitis—Epirubicin—uterine cancer	0.000221	0.000657	CcSEcCtD
Nefazodone—Urinary tract infection—Epirubicin—uterine cancer	0.000221	0.000657	CcSEcCtD
Nefazodone—Dysuria—Doxorubicin—uterine cancer	0.000221	0.000655	CcSEcCtD
Nefazodone—Sweating—Epirubicin—uterine cancer	0.000218	0.000648	CcSEcCtD
Nefazodone—Pollakiuria—Doxorubicin—uterine cancer	0.000218	0.000648	CcSEcCtD
Nefazodone—Haematuria—Epirubicin—uterine cancer	0.000217	0.000644	CcSEcCtD
Nefazodone—ADRA2A—uterine cervix—uterine cancer	0.000216	0.0261	CbGeAlD
Nefazodone—Photosensitivity reaction—Doxorubicin—uterine cancer	0.000216	0.00064	CcSEcCtD
Nefazodone—Weight increased—Doxorubicin—uterine cancer	0.000215	0.000638	CcSEcCtD
Nefazodone—Epistaxis—Epirubicin—uterine cancer	0.000215	0.000637	CcSEcCtD
Nefazodone—Weight decreased—Doxorubicin—uterine cancer	0.000214	0.000634	CcSEcCtD
Nefazodone—Sinusitis—Epirubicin—uterine cancer	0.000214	0.000634	CcSEcCtD
Nefazodone—Feeling abnormal—Etoposide—uterine cancer	0.000213	0.000633	CcSEcCtD
Nefazodone—Nausea—Dactinomycin—uterine cancer	0.000213	0.000631	CcSEcCtD
Nefazodone—Pneumonia—Doxorubicin—uterine cancer	0.000212	0.000629	CcSEcCtD
Nefazodone—Gastrointestinal pain—Etoposide—uterine cancer	0.000212	0.000628	CcSEcCtD
Nefazodone—CYP3A5—renal system—uterine cancer	0.000212	0.0256	CbGeAlD
Nefazodone—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	0.000209	0.00062	CcSEcCtD
Nefazodone—Bradycardia—Epirubicin—uterine cancer	0.000208	0.000617	CcSEcCtD
Nefazodone—Urticaria—Etoposide—uterine cancer	0.000206	0.000611	CcSEcCtD
Nefazodone—ADRA2A—decidua—uterine cancer	0.000205	0.0249	CbGeAlD
Nefazodone—Haemoglobin—Epirubicin—uterine cancer	0.000205	0.000609	CcSEcCtD
Nefazodone—Stomatitis—Doxorubicin—uterine cancer	0.000205	0.000609	CcSEcCtD
Nefazodone—Rhinitis—Epirubicin—uterine cancer	0.000205	0.000608	CcSEcCtD
Nefazodone—Body temperature increased—Etoposide—uterine cancer	0.000205	0.000608	CcSEcCtD
Nefazodone—Abdominal pain—Etoposide—uterine cancer	0.000205	0.000608	CcSEcCtD
Nefazodone—Urinary tract infection—Doxorubicin—uterine cancer	0.000205	0.000607	CcSEcCtD
Nefazodone—Conjunctivitis—Doxorubicin—uterine cancer	0.000205	0.000607	CcSEcCtD
Nefazodone—Hepatitis—Epirubicin—uterine cancer	0.000204	0.000606	CcSEcCtD
Nefazodone—Haemorrhage—Epirubicin—uterine cancer	0.000204	0.000606	CcSEcCtD
Nefazodone—Hypoaesthesia—Epirubicin—uterine cancer	0.000203	0.000603	CcSEcCtD
Nefazodone—Pharyngitis—Epirubicin—uterine cancer	0.000203	0.000602	CcSEcCtD
Nefazodone—Sweating—Doxorubicin—uterine cancer	0.000202	0.000599	CcSEcCtD
Nefazodone—Oedema peripheral—Epirubicin—uterine cancer	0.000201	0.000597	CcSEcCtD
Nefazodone—Haematuria—Doxorubicin—uterine cancer	0.000201	0.000596	CcSEcCtD
Nefazodone—Epistaxis—Doxorubicin—uterine cancer	0.000199	0.000589	CcSEcCtD
Nefazodone—Sinusitis—Doxorubicin—uterine cancer	0.000198	0.000586	CcSEcCtD
Nefazodone—Visual impairment—Epirubicin—uterine cancer	0.000197	0.000584	CcSEcCtD
Nefazodone—ADRA2A—endometrium—uterine cancer	0.000195	0.0236	CbGeAlD
Nefazodone—Erythema multiforme—Epirubicin—uterine cancer	0.000193	0.000573	CcSEcCtD
Nefazodone—Bradycardia—Doxorubicin—uterine cancer	0.000192	0.000571	CcSEcCtD
Nefazodone—Hypersensitivity—Etoposide—uterine cancer	0.000191	0.000566	CcSEcCtD
Nefazodone—Tinnitus—Epirubicin—uterine cancer	0.00019	0.000565	CcSEcCtD
Nefazodone—Haemoglobin—Doxorubicin—uterine cancer	0.00019	0.000564	CcSEcCtD
Nefazodone—Flushing—Epirubicin—uterine cancer	0.00019	0.000563	CcSEcCtD
Nefazodone—Rhinitis—Doxorubicin—uterine cancer	0.00019	0.000562	CcSEcCtD
Nefazodone—Haemorrhage—Doxorubicin—uterine cancer	0.000189	0.000561	CcSEcCtD
Nefazodone—Hepatitis—Doxorubicin—uterine cancer	0.000189	0.000561	CcSEcCtD
Nefazodone—ADRA2A—mammalian vulva—uterine cancer	0.000189	0.0228	CbGeAlD
Nefazodone—Hypoaesthesia—Doxorubicin—uterine cancer	0.000188	0.000558	CcSEcCtD
Nefazodone—Pharyngitis—Doxorubicin—uterine cancer	0.000188	0.000557	CcSEcCtD
Nefazodone—Oedema peripheral—Doxorubicin—uterine cancer	0.000186	0.000553	CcSEcCtD
Nefazodone—Asthenia—Etoposide—uterine cancer	0.000186	0.000551	CcSEcCtD
Nefazodone—HTR2A—epithelium—uterine cancer	0.000185	0.0224	CbGeAlD
Nefazodone—Chills—Epirubicin—uterine cancer	0.000183	0.000544	CcSEcCtD
Nefazodone—Pruritus—Etoposide—uterine cancer	0.000183	0.000544	CcSEcCtD
Nefazodone—Visual impairment—Doxorubicin—uterine cancer	0.000182	0.000541	CcSEcCtD
Nefazodone—Alopecia—Epirubicin—uterine cancer	0.000181	0.000536	CcSEcCtD
Nefazodone—ADRA2A—uterus—uterine cancer	0.00018	0.0218	CbGeAlD
Nefazodone—Erythema multiforme—Doxorubicin—uterine cancer	0.000179	0.00053	CcSEcCtD
Nefazodone—HTR2A—smooth muscle tissue—uterine cancer	0.000178	0.0216	CbGeAlD
Nefazodone—Diarrhoea—Etoposide—uterine cancer	0.000177	0.000526	CcSEcCtD
Nefazodone—Tinnitus—Doxorubicin—uterine cancer	0.000176	0.000523	CcSEcCtD
Nefazodone—Flushing—Doxorubicin—uterine cancer	0.000175	0.000521	CcSEcCtD
Nefazodone—Flatulence—Epirubicin—uterine cancer	0.000175	0.00052	CcSEcCtD
Nefazodone—Dysgeusia—Epirubicin—uterine cancer	0.000174	0.000517	CcSEcCtD
Nefazodone—Back pain—Epirubicin—uterine cancer	0.000172	0.000511	CcSEcCtD
Nefazodone—HTR2A—renal system—uterine cancer	0.000172	0.0208	CbGeAlD
Nefazodone—Dizziness—Etoposide—uterine cancer	0.000171	0.000508	CcSEcCtD
Nefazodone—Muscle spasms—Epirubicin—uterine cancer	0.000171	0.000507	CcSEcCtD
Nefazodone—Chills—Doxorubicin—uterine cancer	0.00017	0.000503	CcSEcCtD
Nefazodone—Vision blurred—Epirubicin—uterine cancer	0.000168	0.000497	CcSEcCtD
Nefazodone—Alopecia—Doxorubicin—uterine cancer	0.000167	0.000496	CcSEcCtD
Nefazodone—Ill-defined disorder—Epirubicin—uterine cancer	0.000165	0.00049	CcSEcCtD
Nefazodone—Vomiting—Etoposide—uterine cancer	0.000165	0.000489	CcSEcCtD
Nefazodone—Anaemia—Epirubicin—uterine cancer	0.000164	0.000488	CcSEcCtD
Nefazodone—Agitation—Epirubicin—uterine cancer	0.000163	0.000485	CcSEcCtD
Nefazodone—Rash—Etoposide—uterine cancer	0.000163	0.000485	CcSEcCtD
Nefazodone—Dermatitis—Etoposide—uterine cancer	0.000163	0.000484	CcSEcCtD
Nefazodone—Headache—Etoposide—uterine cancer	0.000162	0.000481	CcSEcCtD
Nefazodone—Flatulence—Doxorubicin—uterine cancer	0.000162	0.000481	CcSEcCtD
Nefazodone—ADRA2A—female reproductive system—uterine cancer	0.000162	0.0196	CbGeAlD
Nefazodone—Dysgeusia—Doxorubicin—uterine cancer	0.000161	0.000478	CcSEcCtD
Nefazodone—Malaise—Epirubicin—uterine cancer	0.00016	0.000476	CcSEcCtD
Nefazodone—Vertigo—Epirubicin—uterine cancer	0.00016	0.000474	CcSEcCtD
Nefazodone—Syncope—Epirubicin—uterine cancer	0.000159	0.000473	CcSEcCtD
Nefazodone—Leukopenia—Epirubicin—uterine cancer	0.000159	0.000472	CcSEcCtD
Nefazodone—Back pain—Doxorubicin—uterine cancer	0.000159	0.000472	CcSEcCtD
Nefazodone—CYP3A4—renal system—uterine cancer	0.000159	0.0192	CbGeAlD
Nefazodone—Muscle spasms—Doxorubicin—uterine cancer	0.000158	0.00047	CcSEcCtD
Nefazodone—Palpitations—Epirubicin—uterine cancer	0.000157	0.000466	CcSEcCtD
Nefazodone—Loss of consciousness—Epirubicin—uterine cancer	0.000156	0.000464	CcSEcCtD
Nefazodone—CYP2D6—renal system—uterine cancer	0.000156	0.0189	CbGeAlD
Nefazodone—Cough—Epirubicin—uterine cancer	0.000155	0.000461	CcSEcCtD
Nefazodone—Vision blurred—Doxorubicin—uterine cancer	0.000155	0.00046	CcSEcCtD
Nefazodone—ABCB1—myometrium—uterine cancer	0.000154	0.0187	CbGeAlD
Nefazodone—CYP3A5—female gonad—uterine cancer	0.000154	0.0187	CbGeAlD
Nefazodone—Convulsion—Epirubicin—uterine cancer	0.000154	0.000457	CcSEcCtD
Nefazodone—Nausea—Etoposide—uterine cancer	0.000154	0.000456	CcSEcCtD
Nefazodone—Hypertension—Epirubicin—uterine cancer	0.000154	0.000456	CcSEcCtD
Nefazodone—CYP3A5—vagina—uterine cancer	0.000153	0.0185	CbGeAlD
Nefazodone—Ill-defined disorder—Doxorubicin—uterine cancer	0.000153	0.000453	CcSEcCtD
Nefazodone—Anaemia—Doxorubicin—uterine cancer	0.000152	0.000451	CcSEcCtD
Nefazodone—Arthralgia—Epirubicin—uterine cancer	0.000151	0.000449	CcSEcCtD
Nefazodone—Chest pain—Epirubicin—uterine cancer	0.000151	0.000449	CcSEcCtD
Nefazodone—Myalgia—Epirubicin—uterine cancer	0.000151	0.000449	CcSEcCtD
Nefazodone—Agitation—Doxorubicin—uterine cancer	0.000151	0.000449	CcSEcCtD
Nefazodone—Anxiety—Epirubicin—uterine cancer	0.000151	0.000448	CcSEcCtD
Nefazodone—Discomfort—Epirubicin—uterine cancer	0.00015	0.000444	CcSEcCtD
Nefazodone—Malaise—Doxorubicin—uterine cancer	0.000148	0.00044	CcSEcCtD
Nefazodone—Dry mouth—Epirubicin—uterine cancer	0.000148	0.000439	CcSEcCtD
Nefazodone—Vertigo—Doxorubicin—uterine cancer	0.000148	0.000439	CcSEcCtD
Nefazodone—Syncope—Doxorubicin—uterine cancer	0.000148	0.000438	CcSEcCtD
Nefazodone—Leukopenia—Doxorubicin—uterine cancer	0.000147	0.000437	CcSEcCtD
Nefazodone—ADRA2A—female gonad—uterine cancer	0.000147	0.0178	CbGeAlD
Nefazodone—Confusional state—Epirubicin—uterine cancer	0.000146	0.000434	CcSEcCtD
Nefazodone—ADRA2A—vagina—uterine cancer	0.000146	0.0177	CbGeAlD
Nefazodone—Palpitations—Doxorubicin—uterine cancer	0.000145	0.000432	CcSEcCtD
Nefazodone—Anaphylactic shock—Epirubicin—uterine cancer	0.000145	0.000431	CcSEcCtD
Nefazodone—Oedema—Epirubicin—uterine cancer	0.000145	0.000431	CcSEcCtD
Nefazodone—Loss of consciousness—Doxorubicin—uterine cancer	0.000145	0.000429	CcSEcCtD
Nefazodone—Infection—Epirubicin—uterine cancer	0.000144	0.000428	CcSEcCtD
Nefazodone—Cough—Doxorubicin—uterine cancer	0.000144	0.000426	CcSEcCtD
Nefazodone—Shock—Epirubicin—uterine cancer	0.000143	0.000424	CcSEcCtD
Nefazodone—Convulsion—Doxorubicin—uterine cancer	0.000143	0.000423	CcSEcCtD
Nefazodone—Thrombocytopenia—Epirubicin—uterine cancer	0.000142	0.000422	CcSEcCtD
Nefazodone—Hypertension—Doxorubicin—uterine cancer	0.000142	0.000422	CcSEcCtD
Nefazodone—Tachycardia—Epirubicin—uterine cancer	0.000142	0.00042	CcSEcCtD
Nefazodone—Hyperhidrosis—Epirubicin—uterine cancer	0.00014	0.000416	CcSEcCtD
Nefazodone—Myalgia—Doxorubicin—uterine cancer	0.00014	0.000416	CcSEcCtD
Nefazodone—Arthralgia—Doxorubicin—uterine cancer	0.00014	0.000416	CcSEcCtD
Nefazodone—Chest pain—Doxorubicin—uterine cancer	0.00014	0.000416	CcSEcCtD
Nefazodone—Anxiety—Doxorubicin—uterine cancer	0.00014	0.000414	CcSEcCtD
Nefazodone—Discomfort—Doxorubicin—uterine cancer	0.000138	0.000411	CcSEcCtD
Nefazodone—Anorexia—Epirubicin—uterine cancer	0.000138	0.000411	CcSEcCtD
Nefazodone—HTR2A—female reproductive system—uterine cancer	0.000137	0.0166	CbGeAlD
Nefazodone—Dry mouth—Doxorubicin—uterine cancer	0.000137	0.000407	CcSEcCtD
Nefazodone—Hypotension—Epirubicin—uterine cancer	0.000136	0.000403	CcSEcCtD
Nefazodone—Confusional state—Doxorubicin—uterine cancer	0.000135	0.000402	CcSEcCtD
Nefazodone—Anaphylactic shock—Doxorubicin—uterine cancer	0.000134	0.000399	CcSEcCtD
Nefazodone—Oedema—Doxorubicin—uterine cancer	0.000134	0.000399	CcSEcCtD
Nefazodone—SLC6A2—lymph node—uterine cancer	0.000134	0.0162	CbGeAlD
Nefazodone—Infection—Doxorubicin—uterine cancer	0.000133	0.000396	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000132	0.000392	CcSEcCtD
Nefazodone—Shock—Doxorubicin—uterine cancer	0.000132	0.000392	CcSEcCtD
Nefazodone—Thrombocytopenia—Doxorubicin—uterine cancer	0.000132	0.00039	CcSEcCtD
Nefazodone—Insomnia—Epirubicin—uterine cancer	0.000131	0.00039	CcSEcCtD
Nefazodone—Tachycardia—Doxorubicin—uterine cancer	0.000131	0.000389	CcSEcCtD
Nefazodone—Paraesthesia—Epirubicin—uterine cancer	0.00013	0.000387	CcSEcCtD
Nefazodone—Hyperhidrosis—Doxorubicin—uterine cancer	0.00013	0.000385	CcSEcCtD
Nefazodone—Dyspnoea—Epirubicin—uterine cancer	0.000129	0.000384	CcSEcCtD
Nefazodone—Somnolence—Epirubicin—uterine cancer	0.000129	0.000383	CcSEcCtD
Nefazodone—Anorexia—Doxorubicin—uterine cancer	0.000128	0.00038	CcSEcCtD
Nefazodone—Dyspepsia—Epirubicin—uterine cancer	0.000128	0.000379	CcSEcCtD
Nefazodone—CYP3A4—female reproductive system—uterine cancer	0.000127	0.0154	CbGeAlD
Nefazodone—Decreased appetite—Epirubicin—uterine cancer	0.000126	0.000374	CcSEcCtD
Nefazodone—Hypotension—Doxorubicin—uterine cancer	0.000126	0.000372	CcSEcCtD
Nefazodone—CYP2D6—female reproductive system—uterine cancer	0.000125	0.0151	CbGeAlD
Nefazodone—HTR2A—vagina—uterine cancer	0.000124	0.015	CbGeAlD
Nefazodone—Constipation—Epirubicin—uterine cancer	0.000124	0.000368	CcSEcCtD
Nefazodone—Pain—Epirubicin—uterine cancer	0.000124	0.000368	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000122	0.000363	CcSEcCtD
Nefazodone—Insomnia—Doxorubicin—uterine cancer	0.000121	0.000361	CcSEcCtD
Nefazodone—ABCB1—epithelium—uterine cancer	0.000121	0.0147	CbGeAlD
Nefazodone—Paraesthesia—Doxorubicin—uterine cancer	0.000121	0.000358	CcSEcCtD
Nefazodone—ABCB1—uterine cervix—uterine cancer	0.00012	0.0145	CbGeAlD
Nefazodone—Dyspnoea—Doxorubicin—uterine cancer	0.00012	0.000355	CcSEcCtD
Nefazodone—Feeling abnormal—Epirubicin—uterine cancer	0.00012	0.000355	CcSEcCtD
Nefazodone—Somnolence—Doxorubicin—uterine cancer	0.000119	0.000354	CcSEcCtD
Nefazodone—Gastrointestinal pain—Epirubicin—uterine cancer	0.000119	0.000352	CcSEcCtD
Nefazodone—Dyspepsia—Doxorubicin—uterine cancer	0.000118	0.000351	CcSEcCtD
Nefazodone—Decreased appetite—Doxorubicin—uterine cancer	0.000117	0.000346	CcSEcCtD
Nefazodone—Urticaria—Epirubicin—uterine cancer	0.000115	0.000342	CcSEcCtD
Nefazodone—Constipation—Doxorubicin—uterine cancer	0.000115	0.000341	CcSEcCtD
Nefazodone—Pain—Doxorubicin—uterine cancer	0.000115	0.000341	CcSEcCtD
Nefazodone—Body temperature increased—Epirubicin—uterine cancer	0.000115	0.000341	CcSEcCtD
Nefazodone—Abdominal pain—Epirubicin—uterine cancer	0.000115	0.000341	CcSEcCtD
Nefazodone—ABCB1—decidua—uterine cancer	0.000114	0.0139	CbGeAlD
Nefazodone—CYP2D6—female gonad—uterine cancer	0.000114	0.0138	CbGeAlD
Nefazodone—ABCB1—renal system—uterine cancer	0.000112	0.0136	CbGeAlD
Nefazodone—Feeling abnormal—Doxorubicin—uterine cancer	0.000111	0.000328	CcSEcCtD
Nefazodone—Gastrointestinal pain—Doxorubicin—uterine cancer	0.00011	0.000326	CcSEcCtD
Nefazodone—ABCB1—endometrium—uterine cancer	0.000109	0.0132	CbGeAlD
Nefazodone—Hypersensitivity—Epirubicin—uterine cancer	0.000107	0.000317	CcSEcCtD
Nefazodone—Urticaria—Doxorubicin—uterine cancer	0.000107	0.000317	CcSEcCtD
Nefazodone—Body temperature increased—Doxorubicin—uterine cancer	0.000106	0.000315	CcSEcCtD
Nefazodone—Abdominal pain—Doxorubicin—uterine cancer	0.000106	0.000315	CcSEcCtD
Nefazodone—ABCB1—mammalian vulva—uterine cancer	0.000105	0.0127	CbGeAlD
Nefazodone—Asthenia—Epirubicin—uterine cancer	0.000104	0.000309	CcSEcCtD
Nefazodone—Pruritus—Epirubicin—uterine cancer	0.000103	0.000305	CcSEcCtD
Nefazodone—ABCB1—uterus—uterine cancer	0.0001	0.0121	CbGeAlD
Nefazodone—Diarrhoea—Epirubicin—uterine cancer	9.93e-05	0.000295	CcSEcCtD
Nefazodone—Hypersensitivity—Doxorubicin—uterine cancer	9.9e-05	0.000294	CcSEcCtD
Nefazodone—Asthenia—Doxorubicin—uterine cancer	9.64e-05	0.000286	CcSEcCtD
Nefazodone—Dizziness—Epirubicin—uterine cancer	9.6e-05	0.000285	CcSEcCtD
Nefazodone—Pruritus—Doxorubicin—uterine cancer	9.5e-05	0.000282	CcSEcCtD
Nefazodone—ADRA2A—lymph node—uterine cancer	9.45e-05	0.0114	CbGeAlD
Nefazodone—Vomiting—Epirubicin—uterine cancer	9.23e-05	0.000274	CcSEcCtD
Nefazodone—Diarrhoea—Doxorubicin—uterine cancer	9.19e-05	0.000273	CcSEcCtD
Nefazodone—Rash—Epirubicin—uterine cancer	9.15e-05	0.000272	CcSEcCtD
Nefazodone—Dermatitis—Epirubicin—uterine cancer	9.14e-05	0.000271	CcSEcCtD
Nefazodone—Headache—Epirubicin—uterine cancer	9.09e-05	0.00027	CcSEcCtD
Nefazodone—ABCB1—female reproductive system—uterine cancer	9e-05	0.0109	CbGeAlD
Nefazodone—Dizziness—Doxorubicin—uterine cancer	8.88e-05	0.000264	CcSEcCtD
Nefazodone—Nausea—Epirubicin—uterine cancer	8.62e-05	0.000256	CcSEcCtD
Nefazodone—Vomiting—Doxorubicin—uterine cancer	8.54e-05	0.000253	CcSEcCtD
Nefazodone—Rash—Doxorubicin—uterine cancer	8.47e-05	0.000251	CcSEcCtD
Nefazodone—Dermatitis—Doxorubicin—uterine cancer	8.46e-05	0.000251	CcSEcCtD
Nefazodone—Headache—Doxorubicin—uterine cancer	8.41e-05	0.00025	CcSEcCtD
Nefazodone—ABCB1—female gonad—uterine cancer	8.19e-05	0.00991	CbGeAlD
Nefazodone—ABCB1—vagina—uterine cancer	8.14e-05	0.00985	CbGeAlD
Nefazodone—Nausea—Doxorubicin—uterine cancer	7.98e-05	0.000237	CcSEcCtD
Nefazodone—ABCB1—lymph node—uterine cancer	5.27e-05	0.00637	CbGeAlD
